8205 El Rio Street
About InGeneronFounded in 2006, InGeneron is a privately held company, developing its own products for multiple markets and expanding its reach through licensing agreements. The company was formed to innovate cell-based technologies for healthcare and life science research.
CEO: Michael Coleman
CFO: Fabian Alt
15 articles with InGeneron
InGeneron Publishes Overview on Current State and Potential of Regenerative Cell Therapy in Orthopedics
InGeneron, Inc., a clinical stage biotechnology company, announced the publication of a succinct scientific review of regenerative cell therapy, commonly called “stem cell therapy”, to treat orthopedic indications.
American Medical Association Issues New CPT® Category III Codes for InGeneron’s Cell Therapy for Rotator Cuff Tears
InGeneron, Inc., a clinical stage biotechnology company, announced that the American Medical Association’s Current Procedural Terminology Editorial Panel has issued two new Category III CPT® codes for the company’s autologous, adipose-derived regenerative cell therapy for partial thickness rotator cuff tears.
InGeneron Publishes Significant Support for the Existence of Naturally Pluripotent Stem Cells in All Organs in the Adult Body
InGeneron, Inc., a clinical stage regenerative medicine and cell therapy company, announced the publication of the first comprehensive analysis providing significant support for the existence of naturally pluripotent stem cells in all organs.
InGeneron Reports First-In-Human Microscopic Evidence of Adult Tendon Regeneration Following Autologous Stem Cell Treatment
InGeneron, Inc. today announced the publication of the first-in-human comprehensive immunohistochemical evaluation of adult tendon repair following the local injection of fresh, uncultured, unmodified, utologous, adipose derived regenerative cells (UA-ADRCs).
FDA-Approved Randomized Controlled Feasibility Study Finds InGeneron's Regenerative Cell Therapy to Significantly Reduce Pain and Improve Shoulder Function Over Corticosteroid Injection to Address Symptomatic Partial-Thickness Rotator Cuff Tears
InGeneron announces publication of favorable results using regenerative cells isolated from patients’ own body fat prepared with the Transpose® RT System in the Journal of Orthopaedic Surgery and Research.
InGeneron Announces Publication of Preclinical Results for its Cell Therapy in Chronic Ischemic Heart Failure
Animal model for the study of Chronic Myocardial Infarction indicates, for the first time, regenerative potential in a pig’s heart using uncultured autologous adipose-derived regenerative cells prepared at point of care.
InGeneron Extends Series D Financing to $43 Million to Bring Regenerative Cell Therapy into the Clinic
Company raises up to additional $23 million from strategic partner Sanford Health to advance pivotal program in rotator cuff tendinopathy
Company enrolls first patients in multi-center trial evaluating regenerative cell therapy at the point of care for partial rotator cuff tears
Company enrolls first patients in feasibility studies for chronic back pain and wrist osteoarthritis, setting clinical development focus on orthopedic indications
InGeneron Announces Publication Of Positive Results From Investigator-Initiated Wound Healing Case Series Using Company’s Regenerative Cell Technology
InGeneron Announces Presentation Of Results From Investigator Initiated Case Series Of Its Regenerative Cell Therapy In Chronic Back Pain At IFATS